


CLAIMS:

1. A compound of the formula



5

*Sub*  
*an*

wherein A is an L, D or DL amino acid selected from the group consisting of Alanine (Ala), valine (Val), phenylalanine (Phe), para-chloro-phenylalanine (p.Cl Phe), tryptophan (Trp), proline (Pro), serine (Ser), Threonine (Thr), tyrosine (Tyr), glutamic acid (Glu), beta alanine (Beta Ala), -aminobutyric acid (Abu), N-methylalanine (N-Me Ala), 5-fluorotryptophan (5-F Trp), 5-bromotryptophan (5-Br Trp), 5-chlorotryptophan (5-Cl Trp), their acetylated derviatives or a pharmaceutically acceptable acid addition salt thereof;

10

15

B is an L, D or DL amino acid selected from the group consisting of threonine amid (Thr NH<sub>2</sub>), valine amide (Val NH<sub>2</sub>), proline amide (Pro NH<sub>2</sub>), hydroxyproline amide (HO Pro NH<sub>2</sub>), serine amide (Ser NH<sub>2</sub>), tyrosine amide (Tyr NH<sub>2</sub>, tryptophan amide (Trp NH<sub>2</sub>), 5-fluorotryptophan amide (5-F Trp NH<sub>2</sub>), formyl tryptophan amide (For Trp NH<sub>2</sub>), alanine amide (Ala NH<sub>2</sub>), glycine amide (Gly NH<sub>2</sub>) and methylalanine amide (Me Ala NH<sub>2</sub>);

20

X is L-phenylalanine (L-Phe) or L-tyrosine (L-Tyr);

25

Y is L-threonine (L-Thr) or L-valine (L-Val);

Z is L, D or DL 5-halo-tryptophan, in which the halogen (Halo-) is fluorine, chlorine, bromine or iodine, or D-tryptophan (D-Trp); and

C" and C' are L or D-cysteine (Cys),  $\alpha$ -aminobutyric acid (Abu), aspartic acid (Asp) or lysine (Lys);

30

the connecting line between C" and C' signifies a bridge selected from the group consisting of carbon/carbon, carbon/sulfur, sulfur/sulfur and amide bridges; and the pharmaceutically acceptable acid addition salts thereof.

35

2. A compound according to Claim 1 wherein  
C" is Cys;  
X is Phe;  
Z is D-Trp;  
Y is Thr; and  
C' is Cys.

3. A compound according to Claim 1 wherein  
C" is Cys;  
X is Tyr;  
Z is D-Trp;  
Y is Val; and  
C' is Cys.

4. A compound according to Claim 1 wherein  
C" is Cys;  
X is Phe;  
Y is Thr; and  
C' is Cys.

5. A compound according to Claim 1 wherein  
C" is Cys;  
X is Tyr;  
Y is Val; and  
C' is Cys.

6. A compound according to Claim 1 wherein  
C" is Lys;  
X is Tyr;  
Z is D-Trp;  
Y is Val; and  
C' is Asp.

7. A compound according to Claim 1 which is  
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>.

8. A compound according to Claim 1 which is  
Ac-p-Cl-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH<sub>2</sub>.

6  
B 7. A compound according to Claim ~~1~~ <sup>22</sup> which is  
T0420X ~~8-Cl~~-D-Phe-Cys-~~Phe~~<sup>Tyr</sup>-D-Trp-Lys-~~Thr~~<sup>Val</sup>-Cys-~~Thr~~<sup>Val</sup>-NH<sub>2</sub>.


R.C. - A.V.S. 4/18/

B 10. A compound according to Claim ~~1~~ <sup>22</sup> which is  
T0421X Ac ~~8-Cl~~-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH<sub>2</sub>.

R.C. - A.V.S. 4-18


8  
T0422X 11. A compound according to Claim ~~1~~ <sup>22</sup> which is  
Ac-D-Phe-Lys-Tyr-D-Trp-Lys-Val-Asp-Thr-NH<sub>2</sub> (amide bridge).

9  
12. An octapeptide (reduced form) of the formula




wherein A, C'', X, Z, Y, C' and B are as defined in Claim 1.


10  
B 13. A compound according to Claim ~~1~~ <sup>22</sup> which is:



11  
14. A compound according to Claim ~~1~~ <sup>9</sup> which is:




12  
15. A compound according to Claim ~~1~~ <sup>9</sup> which is:




R.C. A.V.S. 4-18.

16. A process for preparing an octapeptide of formula (I)



in which A, C'', X, Z, Y, C' and B are as defined in Claim 1 which comprises oxidizing a corresponding peptide of formula (II)



in which A, C'', X, Z, Y, C' and B are as defined above.

17. The process of Claim 16 wherein the peptide of formula (I') is oxidized with potassium ferricyanide, iodine, oxygen or air.

B

14  
18.

A pharmaceutical composition which comprises an octapeptide of Claim 1, its reduced form or a pharmaceutically acceptable acid addition salt thereof in a pharmaceutically acceptable liquid or solid carrier thereof.

15

19. A pharmaceutical composition of Claim 14 which

~~comprises an octapeptide of Claim 1, its reduced form or a pharmaceutically acceptable acid addition salt thereof,~~  
encapsulated in poly (d,l-lactide-co-glycolide) microcapsules.

16


20. A method of treating excess release of growth

hormone, gastrointestinal disorders, ~~cancer~~ and diabetes in a mammal in need of such therapy which comprises administering to said mammal an effective dose of octapeptide of Claim 1, its reduced form, or a pharmaceutically acceptable acid addition salt thereof.

(P.C.-Arg)  
(P.C.-Arg)  
(P.C.-Arg)  
(4/18/85)

13  
21

A COMPOUND ACCORDING TO CLAIM 12 WHICH IS:



add B17

43